The role of danger signals and ectonucleotidases in acute graft-versus-host disease

Human Immunology

Volumn 77, Issue 11, 2016, Pages 1037-1047

  Apostolova, Petya ^a   Zeiser, Robert ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adenosine; Allogeneic hematopoietic cell transplantation; ATP; DAMP; Ectonucleotidase; Graft versus host disease; Heat shock protein; HMGB1; Inflammasome; S100 protein family; Uric acid

Indexed keywords

ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; BIOLOGICAL FACTOR; CYCLIN DEPENDENT KINASE; DANGER ASSOCIATED MOLECULAR PATTERN; ECTONUCLEOTIDASE; HEAT SHOCK PROTEIN; HEPARAN SULFATE; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 12; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NUCLEOTIDASE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PROTEIN KINASE SYK; PROTEIN S 100; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC RECEPTOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; URIC ACID; APYRASE; CD39 ANTIGEN; INORGANIC PYROPHOSPHATASE; LEUKOCYTE ANTIGEN; PATTERN RECOGNITION RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADAPTIVE IMMUNITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOREACTIVE T CELL; ANTIGEN PRESENTING CELL; ARTICLE; ENERGY RESOURCE; EXTRACELLULAR MATRIX; HUMAN; INNATE IMMUNITY; INTRACELLULAR SPACE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ACUTE DISEASE; ALLOTRANSPLANTATION; ANIMAL; COMPLICATION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD; APYRASE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, INNATE; PYROPHOSPHATASES; RECEPTORS, PATTERN RECOGNITION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84964397441     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2016.02.005     Document Type: Article

References (174)

1. [1] Ferrara, J.L., Levine, J.E., Reddy, P., Holler, E., Graft-versus-host disease. Lancet, 373, 2009, 1550.
2. [2] Blazar, B.R., Murphy, W.J., Abedi, M., Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol., 12, 2012, 443.
3. [3] Matzinger, P., Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12, 1994, 991.
4. [4] Skoberne, M., Beignon, A.S., Bhardwaj, N., Danger signals: a time and space continuum. Trends Mol. Med., 10, 2004, 251.
5. [5] Schaefer, L., Complexity of danger: the diverse nature of damage-associated molecular patterns. J. Biol. Chem., 289, 2014, 35237.
6. [6] Wilkin, F., Duhant, X., Bruyns, C., Suarez-Huerta, N., Boeynaems, J.M., Robaye, B., The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J. Immunol., 166, 2001, 7172.
7. [7] Schnurr, M., Then, F., Galambos, P., Scholz, C., Siegmund, B., Endres, S., et al. Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J. Immunol., 165, 2000, 4704.
8. [8] Shi, Y., Evans, J.E., Rock, K.L., Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 425, 2003, 516.
9. [9] Millar, D.G., Garza, K.M., Odermatt, B., Elford, A.R., Ono, N., Li, Z., et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat. Med., 9, 2003, 1469.
10. [10] Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 418, 2002, 191.
11. [11] Park, J.S., Svetkauskaite, D., He, Q., Kim, J.Y., Strassheim, D., Ishizaka, A., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem., 279, 2004, 7370.
12. [12] Van Crombruggen, K., Vogl, T., Pérez-Novo, C., Holtappels, G., Bachert, C., Differential release and deposition of S100A8/A9 proteins in inflamed upper airway tissue. Eur. Respir. J., 47, 2016, 264.
13. [13] Reinhardt, K., Foell, D., Vogl, T., Mezger, M., Wittkowski, H., Fend, F., et al. Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease. J. Immunol., 193, 2014, 3355.
14. [14] Babelova, A., Moreth, K., Tsalastra-Greul, W., Zeng-Brouwers, J., Eickelberg, O., Young, M.F., et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem., 284, 2009, 24035.
15. [15] Schaefer, L., Babelova, A., Kiss, E., Hausser, H.J., Baliova, M., Krzyzankova, M., et al. The matrix component biglycan is proinflammatory and signals through toll-like receptors 4 and 2 in macrophages. J. Clin. Invest., 115, 2005, 2223.
16. [16] Goodall, K.J., Poon, I.K., Phipps, S., Hulett, M.D., Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS ONE, 9, 2014, e109596.
17. [17] Okamura, Y., Watari, M., Jerud, E.S., Young, D.W., Ishizaka, S.T., Rose, J., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem., 276, 2001, 10229.
18. [18] Smiley, S.T., King, J.A., Hancock, W.W., Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol., 167, 2001, 2887.
19. [19] Ramadan, A., Paczesny, S., Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation. Front. Immunol., 6, 2015, 14.
20. [20] Kawai, T., Akira, S., Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 34, 2011, 637.
21. [21] Akira, S., Uematsu, S., Takeuchi, O., Pathogen recognition and innate immunity. Cell, 124, 2006, 783.
22. [22] Kawasaki, T., Kawai, T., Toll-like receptor signaling pathways. Front. Immunol., 5, 2014, 461.
23. [23] Franchi, L., Warner, N., Viani, K., Nunez, G., Function of Nod-like receptors in microbial recognition and host defense. Immunol. Rev., 227, 2009, 106.
24. [24] Junger, W.G., Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol., 11, 2011, 201.
25. [25] Zeiser, R., Penack, O., Holler, E., Idzko, M., Danger signals activating innate immunity in graft-versus-host disease. J. Mol. Med. (Berl), 89, 2011, 833.
26. [26] Pizzirani, C., Ferrari, D., Chiozzi, P., Adinolfi, E., Sandona, D., Savaglio, E., et al. Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. Blood, 109, 2007, 3856.
27. [27] Ferrari, D., La Sala, A., Chiozzi, P., Morelli, A., Falzoni, S., Girolomoni, G., et al. The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J., 14, 2000, 2466.
28. [28] Idzko, M., Dichmann, S., Ferrari, D., Di Virgilio, F., la Sala, A., Girolomoni, G., et al. Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood, 100, 2002, 925.
29. [29] la Sala, A., Sebastiani, S., Ferrari, D., Di Virgilio, F., Idzko, M., Norgauer, J., et al. Dendritic cells exposed to extracellular adenosine triphosphate acquire the migratory properties of mature cells and show a reduced capacity to attract type 1 T lymphocytes. Blood, 99, 2002, 1715.
30. [30] Schnurr, M., Toy, T., Stoitzner, P., Cameron, P., Shin, A., Beecroft, T., et al. ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood, 102, 2003, 613.
31. [31] Idzko, M., Hammad, H., van Nimwegen, M., Kool, M., Willart, M.A., Muskens, F., et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat. Med., 13, 2007, 913.
32. [32] Schwab, L., Goroncy, L., Palaniyandi, S., Gautam, S., Triantafyllopoulou, A., Mocsai, A., et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat. Med., 20, 2014, 648.
33. [33] Khine, A.A., Del Sorbo, L., Vaschetto, R., Voglis, S., Tullis, E., Slutsky, A.S., et al. Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway. Blood, 107, 2006, 2936.
34. [34] Alkayed, F., Kashimata, M., Koyama, N., Hayashi, T., Tamura, Y., Azuma, Y., P2Y11 purinoceptor mediates the ATP-enhanced chemotactic response of rat neutrophils. J. Pharmacol. Sci., 120, 2012, 288.
35. [35] Miyazawa, M., Ito, Y., Kosaka, N., Nukada, Y., Sakaguchi, H., Suzuki, H., et al. Role of TNF-alpha and extracellular ATP in THP-1 cell activation following allergen exposure. J. Toxicol. Sci., 33, 2008, 71.
36. [36] Gavala, M.L., Pfeiffer, Z.A., Bertics, P.J., The nucleotide receptor P2RX7 mediates ATP-induced CREB activation in human and murine monocytic cells. J. Leukoc. Biol., 84, 2008, 1159.
37. [37] Rizzo, R., Ferrari, D., Melchiorri, L., Stignani, M., Gulinelli, S., Baricordi, O.R., et al. Extracellular ATP acting at the P2X7 receptor inhibits secretion of soluble HLA-G from human monocytes. J. Immunol., 183, 2009, 4302.
38. [38] Ben Yebdri, F., Kukulski, F., Tremblay, A., Sevigny, J., Concomitant activation of P2Y(2) and P2Y(6) receptors on monocytes is required for TLR1/2-induced neutrophil migration by regulating IL-8 secretion. Eur. J. Immunol., 39, 2009, 2885.
39. [39] Hanley, P.J., Musset, B., Renigunta, V., Limberg, S.H., Dalpke, A.H., Sus, R., et al. Extracellular ATP induces oscillations of intracellular Ca2+ and membrane potential and promotes transcription of IL-6 in macrophages. Proc. Natl. Acad. Sci. U.S.A., 101, 2004, 9479.
40. [40] Wilhelm, K., Ganesan, J., Muller, T., Durr, C., Grimm, M., Beilhack, A., et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat. Med., 16, 2010, 1434.
41. [41] Cassel, S.L., Joly, S., Sutterwala, F.S., The NLRP3 inflammasome: a sensor of immune danger signals. Semin. Immunol., 21, 2009, 194.
42. [42] Chen, S., Smith, B.A., Iype, J., Prestipino, A., Pfeifer, D., Grundmann, S., Schmitt-Graeff, A., Idzko, M., Beck, Y., Prinz, G., Finke, J., Duyster, J., Zeiser, R., MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood, 126, 2015, 103.
43. [43] Jankovic, D., Ganesan, J., Bscheider, M., Stickel, N., Weber, F.C., Guarda, G., et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J. Exp. Med., 210, 2013, 1899.
44. [44] Klämbt, V., Wohlfeil, S.A., Schwab, L., Hülsdünker, J., Ayata, K., Apostolova, P., Schmitt-Graeff, A., Dierbach, H., Prinz, G., Follo, K., Prinz, M., Idzko, M., Zeiser, R., A novel function for P2Y2 in myeloid recipient-derived cells during GvHD. J. Immunol., 195, 2015, 5795.
45. [45] Lee, K.H., Park, S.S., Kim, I., Kim, J.H., Ra, E.K., Yoon, S.S., Hong, Y.C., Park, S., Kim, B.K., P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Haematologica, 92, 2007, 651.
46. [46] Holler, E., Rogler, G., Herfarth, H., Brenmoehl, J., Wild, P.J., Hahn, J., Eissner, G., Schoelmerich, J., Andreesen, R., Both, donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood, 2004.
47. [47] Holler, E., Rogler, G., Brenmoehl, J., Hahn, J., Herfarth, H., Greinix, H., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood, 107, 2006, 4189.
48. [48] van der Velden, W.J., Blijlevens, N.M., Maas, F.M., Schaap, N.P., Jansen, J.H., van der Reijden, B.A., Feuth, T., Dolstra, H., Donnelly, J.P., NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. Bone Marrow Transplant., 44, 2009, 243.
49. [49] Granell, M., Urbano-Ispizua, A., Arostegui, J.I., Fernandez-Aviles, F., Martinez, C., Rovira, M., et al. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica, 9, 2006, 1372.
50. [50] Tanabe, T., Yamaguchi, N., Matsuda, K., Yamazaki, K., Takahashi, S., Tojo, A., Association analysis of the NOD2 gene with susceptibility to graft-versus-host disease in a Japanese population. Int. J. Hematol., 93, 2011, 771.
51. [51] Resende, R.G., Abreu, M.H., de Souza, L.N., Silva, M.E., Gomez, R.S., Correia-Silva, F., Association between IL1B (+3954) polymorphisms and IL-1β levels in blood and saliva, together with acute graft-versus-host disease. J. Interferon Cytokine Res., 33, 2013, 392.
52. [52] Koziak, K., Sevigny, J., Robson, S.C., Siegel, J.B., Kaczmarek, E., Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb. Haemost., 82, 1999, 1538.
53. [53] Kaczmarek, E., Koziak, K., Sevigny, J., Siegel, J.B., Anrather, J., Beaudoin, A.R., et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J. Biol. Chem., 271, 1996, 33116.
54. [54] Thompson, L.F., Ruedi, J.M., Glass, A., Low, M.G., Lucas, A.H., Antibodies to 5’-nucleotidase (CD73), a glycosyl-phosphatidylinositol-anchored protein, cause human peripheral blood T cells to proliferate. J. Immunol., 143, 1989, 1815.
55. [55] Strohmeier, G.R., Lencer, W.I., Patapoff, T.W., Thompson, L.F., Carlson, S.L., Moe, S.J., et al. Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J. Clin. Invest., 99, 1997, 2588.
56. [56] Deaglio, S., Dwyer, K.M., Gao, W., Friedman, D., Usheva, A., Erat, A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med., 204, 2007, 1257.
57. [57] Alam, M.S., Kurtz, C.C., Rowlett, R.M., Reuter, B.K., Wiznerowicz, E., Das, S., et al. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J. Infect. Dis., 199, 2009, 494.
58. [58] Dwyer, K.M., Hanidziar, D., Putheti, P., Hill, P.A., Pommey, S., McRae, J.L., et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am. J. Transplant., 10, 2010, 2410.
59. [59] Sauer, A.V., Brigida, I., Carriglio, N., Hernandez, R.J., Scaramuzza, S., Clavenna, D., et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood, 119, 2012, 1428.
60. [60] Sattler, C., Steinsdoerfer, M., Offers, M., Fischer, E., Schierl, R., Heseler, K., et al. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant., 20, 2011, 1221.
61. [61] Saldanha-Araujo, F., Ferreira, F.I., Palma, P.V., Araujo, A.G., Queiroz, R.H., Covas, D.T., et al. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res., 7, 2011, 66.
62. [62] Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C.G., Strober, S., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med., 9, 2003, 1144.
63. [63] Hoffmann, P., Ermann, J., Edinger, M., Fathman, C.G., Strober, S., Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med., 196, 2002, 389.
64. [64] Taylor, P.A., Lees, C.J., Blazar, B.R., The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood, 99, 2002, 3493.
65. [65] Zeiser, R., Nguyen, V.H., Beilhack, A., Buess, M., Schulz, S., Baker, J., Contag, C.H., Negrin, R.S., Inhibition of CD4+CD25+ regulatory T cell function by calcineurin dependent interleukin-2 production. Blood, 108, 2006, 390.
66. [66] Dürr, C., Follo, M., Idzko, M., Reichardt, W., Zeiser, R., Graft-versus-host disease reduces regulatory T cell migration into the tumour tissue. Immunology, 137, 2012, 80.
67. [67] Jones, S.C., Murphy, G.F., Korngold, R., Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol. Blood Marrow Transplant., 9, 2003, 243.
68. [68] Jenabian, M.A., Seddiki, N., Yatim, A., Carriere, M., Hulin, A., Younas, M., et al. Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathog., 9, 2013, e1003319.
69. [69] Kinsey, G.R., Huang, L., Jaworska, K., Khutsishvili, K., Becker, D.A., Ye, H., et al. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J. Am. Soc. Nephrol., 23, 2012, 1528.
70. [70] Han, K.L., Thomas, S.V., Koontz, S.M., Changpriroa, C.M., Ha, S.K., Malech, H.L., et al. Adenosine A(2)A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease. J. Immunol., 190, 2013, 458.
71. [71] Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., Sitkovsky, M., The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front. Immunol., 3, 2012, 190.
72. [72] Lappas, C.M., Liu, P.C., Linden, J., Kang, E.M., Malech, H.L., Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation. J. Leukoc. Biol., 87, 2010, 345.
73. [73] Jones, K.R., Kang, E.M., Graft versus host disease: new insights into A2A receptor agonist therapy. Comput. Struct. Biotechnol. J., 13, 2015, 101.
74. [74] Maitra, B., Szekely, E., Gjini, K., Laughlin, M.J., Dennis, J., Haynesworth, S.E., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant., 33, 2004, 597.
75. [75] Le Blanc, K., Rasmusson, I., Sundberg, B., Gotherstrom, C., Hassan, M., Uzunel, M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363, 2004, 1439.
76. [76] Aggarwal, S., Pittenger, M.F., Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105, 2005, 1815.
77. [77] Amarnath, S., Foley, J.E., Farthing, D.E., Gress, R.E., Laurence, A., Eckhaus, M.A., et al. Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo. Stem Cells, 33, 2015, 1200.
78. [78] Tsukamoto, H., Chernogorova, P., Ayata, K., Gerlach, U.V., Rughani, A., Ritchey, J.W., et al. Deficiency of CD73/ecto-5’-nucleotidase in mice enhances acute graft-versus-host disease. Blood, 119, 2012, 4554.
79. [79] Wang, L., Fan, J., Chen, S., Zhang, Y., Curiel, T.J., Zhang, B., Graft-versus-host disease is enhanced by selective CD73 blockade in mice. PLoS ONE, 8, 2013, e58397.
80. [80] Höckel, M., Vaupel, P., Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst., 93, 2001, 266.
81. [81] Vaupel, P., Mayer, A., Can respiratory hyperoxia mitigate adenosine-driven suppression of antitumor immunity?. Ann. Transl. Med., 292, 2015, 2305.
82. [82] Busse, M., Vaupel, P., Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia. Experientia, 52, 1996, 469.
83. [83] Hatfield, S.M., Kjaergaard, J., Lukashev, D., Schreiber, T.H., Belikoff, B., et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl. Med., 7, 2015, 277ra30.
84. [84] Waickman, A.T., Alme, A., Senaldi, L., Zarek, P.E., Horton, M., Powell, J.D., Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol. Immunother., 61, 2012, 917.
85. [85] Leone, R.D., Lo, Y.C., Powell, J.D., A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput. Struct. Biotechnol. J., 13, 2015, 265.
86. [86] Iannone, R., Miele, L., Maiolino, P., Pinto, A., Morello, S., Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia, 12, 2013, 1400.
87. [87] Wei, Q., Costanzi, S., Balasubramanian, R., Gao, Z.G., Jacobson, K.A., A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal, 2, 2013, 271.
88. [88] Hatfield, S.M., Kjaergaard, J., Lukashev, D., Belikoff, B., Schreiber, T.H., Sethumadhavan, S., et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J. Mol. Med., 92, 2014, 1283.
89. [89] Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., Tschopp, J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440, 2006, 237.
90. [90] Gasse, P., Riteau, N., Charron, S., Girre, S., Fick, L., Petrilli, V., et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Respir. Crit. Care Med., 179, 2009, 903.
91. [91] Webb, R., Jeffries, M., Sawalha, A.H., Uric acid directly promotes human T-cell activation. Am. J. Med. Sci., 337, 2009, 23.
92. [92] Conforti-Andreoni, C., Spreafico, R., Qian, H.L., Riteau, N., Ryffel, B., Ricciardi-Castagnoli, P., et al. Uric acid-driven Th17 differentiation requires inflammasome-derived IL-1 and IL-18. J. Immunol., 187, 2011, 5842.
93. [93] Carlson, M.J., West, M.L., Coghill, J.M., Panoskaltsis-Mortari, A., Blazar, B.R., Serody, J.S., In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood, 113, 2009, 1365.
94. [94] Zhao, X.Y., Xu, L.L., Lu, S.Y., Huang, X.J., IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur. J. Immunol., 41, 2011, 514.
95. [95] Fulton, L.M., Carlson, M.J., Coghill, J.M., Ott, L.E., West, M.L., Panoskaltsis-Mortari, A., et al. Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORgammat. J. Immunol., 189, 2012, 1765.
96. [96] Yeh, A.C., Brunner, A.M., Spitzer, T.R., Chen, Y.B., Coughlin, E., McAfee, S., et al. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol. Blood Marrow Transplant., 20, 2014, 730.
97. [97] Ostendorf, B.N., Blau, O., Uharek, L., Blau, I.W., Penack, O., Association between low uric acid levels and acute graft-versus-host disease. Ann. Hematol., 94, 2015, 139.
98. [98] Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 23, 2005, 479.
99. [99] Moussion, C., Ortega, N., Girard, J.P., The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PLoS ONE, 3, 2008, e3331.
100. [100] Liew, F.Y., Pitman, N.I., McInnes, I.B., Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol., 10, 2010, 103.
101. [101] Byrne, S.N., Beaugie, C., O'Sullivan, C., Leighton, S., Halliday, G.M., The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am. J. Pathol., 179, 2011, 211.
102. [102] Yang, Q., Li, G., Zhu, Y., Liu, L., Chen, E., Turnquist, H., et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur. J. Immunol., 41, 2011, 3351.
103. [103] Besnard, A.G., Togbe, D., Guillou, N., Erard, F., Quesniaux, V., Ryffel, B., IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur. J. Immunol., 41, 2011, 1675.
104. [104] Vander Lugt, M.T., Braun, T.M., Hanash, S., Ritz, J., Ho, V.T., Antin, J.H., et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N. Engl. J. Med., 369, 2013, 529.
105. [105] Ponce, D.M., Hilden, P., Mumaw, C., Devlin, S.M., Lubin, M., Giralt, S., et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood, 125, 2015, 199.
106. [106] Nelson, R.P. Jr., Khawaja, M.R., Perkins, S.M., Elmore, L., Mumaw, C.L., Orschell, C., et al. Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation. Biol. Blood Marrow Transplant., 20, 2014, 1861.
107. [107] Levine, J.E., Braun, T.M., Harris, A.C., Holler, E., Taylor, A., Miller, H., et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Lancet Haematol., 2, 2015, e21.
108. [108] Reichenbach, D.K., Schwarze, V., Matta, B.M., Tkachev, V., Lieberknecht, E., Liu, Q., et al. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood, 125, 2015, 3183.
109. [109] Zhang, J., Ramadan, A.M., Griesenauer, B., Li, W., Turner, M.J., Liu, C., Kapur, R., Hanenberg, H., Blazar, B.R., Tawara, I., Paczesny, S., ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci. Transl. Med., 308, 2015, 308ra160.
110. [110] Klune, J.R., Dhupar, R., Cardinal, J., Billiar, T.R., Tsung, A., HMGB1: endogenous danger signaling. Mol. Med., 14, 2008, 476.
111. [111] Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J.M., Ombrellino, M., Che, J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science, 285, 1999, 248.
112. [112] Liu, S., Stolz, D.B., Sappington, P.L., Macias, C.A., Killeen, M.E., Tenhunen, J.J., et al. HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am. J. Physiol. Cell Physiol., 290, 2006, C990.
113. [113] Rovere-Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catalanotti, F., Giazzon, M., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep., 5, 2004, 825.
114. [114] Messmer, D., Yang, H., Telusma, G., Knoll, F., Li, J., Messmer, B., et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol., 173, 2004, 307.
115. [115] Dumitriu, I.E., Baruah, P., Valentinis, B., Voll, R.E., Herrmann, M., Nawroth, P.P., et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol., 174, 2005, 7506.
116. [116] Yang, D., Chen, Q., Yang, H., Tracey, K.J., Bustin, M., Oppenheim, J.J., High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol., 81, 2007, 59.
117. [117] Manfredi, A.A., Capobianco, A., Esposito, A., De Cobelli, F., Canu, T., Monno, A., et al. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol., 180, 2008, 2270.
118. [118] Dumitriu, I.E., Bianchi, M.E., Bacci, M., Manfredi, A.A., Rovere-Querini, P., The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol., 81, 2007, 84.
119. [119] Campana, L., Bosurgi, L., Bianchi, M.E., Manfredi, A.A., Rovere-Querini, P., Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol., 86, 2009, 609.
120. [120] Im, K.I., Kim, N., Lim, J.Y., Nam, Y.S., Lee, E.S., Kim, E.J., et al. The free radical scavenger NecroX-7 attenuates acute graft-versus-host disease via reciprocal regulation of Th1/regulatory T cells and inhibition of HMGB1 release. J. Immunol., 194, 2015, 5223.
121. [121] Xu, Y.J., Li, L., Chen, Y., Fu, B., Wu, D.S., Li, X.L., et al. Role of HMGB1 in regulation of STAT3 expression in CD4 T cells from patients with aGVHD after allogeneic hematopoietic stem cell transplantation. Clin. Immunol., 2015.
122. [122] Kornblit, B., Masmas, T., Petersen, S.L., Madsen, H.O., Heilmann, C., Schejbel, L., et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 16, 2010, 239.
123. [123] Yujiri, T., Tagami, K., Tanaka, Y., Mitani, N., Nakamura, Y., Ariyoshi, K., et al. Increased serum levels of high-mobility group box 1 protein in patients who developed acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Eur. J. Haematol., 85, 2010, 366.
124. [124] Chen, G.Y., Tang, J., Zheng, P., Liu, Y., CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science, 323, 2009, 1722.
125. [125] Liu, Y., Chen, G.Y., Zheng, P., CD24-Siglec G/10 discriminates danger-from pathogen-associated molecular patterns. Trends Immunol., 30, 2009, 557.
126. [126] Toubai, T., Hou, G., Mathewson, N., Liu, C., Wang, Y., Oravecz-Wilson, K., et al. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood, 123, 2014, 3512.
127. [127] Hofmann, M.A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 97, 1999, 889.
128. [128] Sorci, G., Giovannini, G., Riuzzi, F., Bonifazi, P., Zelante, T., Zagarella, S., Bistoni, F., Donato, R., Romani, L., The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation. PLoS Pathog., 7, 2011, e1001315.
129. [129] Rohde, D., Schön, C., Boerries, M., Didrihsone, I., Ritterhoff, J., et al. S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via toll-like receptor 4. EMBO Mol. Med., 6, 2014, 778.
130. [130] Chiusolo, P., Giammarco, S., Fanali, C., Bellesi, S., Metafuni, E., Sica, S., Iavarone, F., Cabras, T., Messana, I., Leone, G., Castagnola, M., Salivary proteomic analysis and acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant., 19, 2013, 888.
131. [131] Aomatsu, T., Yoden, A., Matsumoto, K., Kimura, E., Inoue, K., Andoh, A., Tamai, H., Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig. Dis. Sci., 56, 2011, 2372.
132. [132] Cunha, C., Giovannini, G., Pierini, A., Bell, A.S., Sorci, G., Riuzzi, F., Donato, R., Rodrigues, F., Velardi, A., Aversa, F., Romani, L., Carvalho, A., Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients. PLoS ONE, 11, 2011, e27962.
133. [133] Schmitt, E., Gehrmann, M., Brunet, M., Multhoff, G., Garrido, C., Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol., 81, 2007, 15.
134. [134] Arnold-Schild, D., Hanau, D., Spehner, D., Schmid, C., Rammensee, H.G., de la Salle, H., Schild, H., Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol., 162, 1999, 3757.
135. [135] Wang, Y., Kelly, C.G., Singh, M., McGowan, E.G., Carrara, A.S., Bergmeier, L.A., Lehner, T., Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J. Immunol., 169, 2002, 2422.
136. [136] Asea, A., Kraeft, S.K., Kurt-Jones, E.A., Stevenson, M.A., Chen, L.B., Finberg, R.W., Koo, G.C., Calderwood, S.K., HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med., 6, 2000, 435.
137. [137] Goral, J., Mathews, H.L., Clancy, J. Jr., Expression of 70-kDa heat-shock protein during acute graft-versus-host disease. Clin. Immunol. Immunopathol., 86, 1998, 252.
138. [138] Goral, J., Mathews, H.L., Clancy, J. Jr., Antibodies specific for the 70-kDa heat-shock protein parallel the development of acute graft-versus-host disease in (DA × LEW)F1 rats. Clin. Immunol. Immunopathol., 75, 1995, 147.
139. [139] Novota, P., Sviland, L., Zinocker, S., Stocki, P., Balavarca, Y., Bickeboller, H., et al. Correlation of Hsp70-1 and Hsp70-2 gene expression with the degree of graft-versus-host reaction in a rat skin explant model. Transplantation, 85, 2008, 1809.
140. [140] Goral, J., Mathews, H.L., Nadler, S.G., Clancy, J., Reduced levels of Hsp70 result in a therapeutic effect of 15-deoxyspergualin on acute graft-versus-host disease in (DA × LEW)F1 rats. Immunobiology, 202, 2000, 254.
141. [141] Stuehler, C., Mielke, S., Chatterjee, M., Duell, J., Lurati, S., Rueckert, F., et al. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood, 114, 2009, 2829.
142. [142] Berges, C., Bedke, T., Stuehler, C., Khanna, N., Zehnter, S., Kruhm, M., et al. Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs. J. Leukoc. Biol., 2015.
143. [143] Goral, J., Shenoy, S., Mohanakumar, T., Clancy, J. Jr., Antibodies to 70 kD and 90 kD heat shock proteins are associated with graft-versus-host disease in peripheral blood stem cell transplant recipients. Clin. Exp. Immunol., 127, 2002, 553.
144. [144] Jarvis, M., Marzolini, M., Wang, X.N., Jackson, G., Sviland, L., Dickinson, A.M., Heat shock protein 70: correlation of expression with degree of graft-versus-host response and clinical graft-versus-host disease. Transplantation, 76, 2003, 849.
145. [145] Bogunia-Kubik, K., Lange, A., HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation, 79, 2005, 815.
146. [146] Wight, T.N., Kinsella, M.G., Qwarnstrom, E.E., The role of proteoglycans in cell adhesion, migration and proliferation. Curr. Opin. Cell Biol., 4, 1992, 793.
147. [147] Kodaira, Y., Nair, S.K., Wrenshall, L.E., Gilboa, E., Platt, J.L., Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. J. Immunol., 165, 2000, 1599.
148. [148] Johnson, G.B., Brunn, G.J., Kodaira, Y., Platt, J.L., Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by toll-like receptor 4. J. Immunol., 168, 2002, 5233.
149. [149] Brennan, T.V., Lin, L., Huang, X., Cardona, D.M., Li, Z., Dredge, K., et al. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood, 120, 2012, 2899.
150. [150] Tawara, I., Sun, Y., Lewis, E.C., Toubai, T., Evers, R., Nieves, E., et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc. Natl. Acad. Sci. U.S.A., 109, 2012, 564.
151. [151] Marcondes, A.M., Li, X., Tabellini, L., Bartenstein, M., Kabacka, J., Sale, G.E., et al. Inhibition of IL-32 activation by alpha-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood, 118, 2011, 5031.
152. [152] Marcondes, A.M., Karoopongse, E., Lesnikova, M., Margineantu, D., Welte, T., Dinarello, C.A., et al. Alpha-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood, 124, 2014, 2881.
153. [153] Rodriguez-Otero, P., Porcher, R., Peffault de Latour, R., Contreras, M., Bouhnik, Y., Xhaard, A., et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood, 119, 2012, 5909.
154. [154] Giroux, M., Delisle, J.S., Gauthier, S.D., Heinonen, K.M., Hinsinger, J., Houde, B., et al. SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage. Blood, 117, 2011, 1734.
155. [155] Penack, O., Smith, O.M., Cunningham-Bussel, A., Liu, X., Rao, U., Yim, N., et al. NOD2 regulates hematopoietic cell function during graft-versus-host disease. J. Exp. Med., 206, 2009, 2101.
156. [156] Toubai, T., Hou, G., Mathewson, N., Liu, C., Wang, Y., Oravecz-Wilson, K., Cummings, E., Rossi, C., Evers, R., Sun, Y., Wu, J., Choi, S.W., Fang, D., Zheng, P., Liu, Y., Reddy, P., Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood, 2014 [Epub ahead of print].
157. [157] Parkman, R., Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J. Immunol., 136, 1986, 3543.
158. [158] Jones, S.C., Friedman, T.M., Murphy, G.F., Korngold, R., Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Biol. Blood Marrow Transplant., 10, 2004, 91.
159. [159] Rangarajan, H., Yassai, M., Subramanian, H., Komorowski, R., Whitaker, M., Gorski, J., Drobyski, W.R., Emergence of T cells that recognize nonpolymorphic antigens during graft-versus-host disease. Blood, 119, 2012, 6354.
160. [160] Hechinger, A.K., Smith, B.A., Flynn, R., Hanke, K., McDonald-Hyman, C., Taylor, P.A., Pfeifer, D., Hackanson, B., Leonhardt, F., Prinz, G., Dierbach, H., Schmitt-Graeff, A., Kovarik, J., Blazar, B.R., Zeiser, R., Therapeutic activity of multiple common gamma chain cytokine inhibition in acute and chronic GvHD. Blood, 125, 2015, 570.
161. [161] Reddy, P., Sun, Y., Toubai, T., Duran-Struuck, R., Clouthier, S.G., Weisiger, E., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest., 118, 2008, 2562.
162. [162] Choi, S.W., Braun, T., Chang, L., Ferrara, J.L., Pawarode, A., Magenau, J.M., et al. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol., 15, 2014, 87.
163. [163] Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S.K., et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey. Leukemia, 29, 2015, 2062.
164. [164] Leonhardt, F., Zirlik, K., Buchner, M., Prinz, G., Hechinger, A.K., Gerlach, U.V., Fisch, P., Schmitt-Gräff, A., Reichardt, W., Zeiser, R., Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia, 26, 2012, 1617.
165. [165] Nellore, A., Liu, B., Patsoukis, N., Boussiotis, V.A., Li, L., The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors. Clin. Immunol., 152, 2014, 48.
166. [166] Shindo, T., Kim, T.K., Benjamin, C.L., Wieder, E.D., Levy, R.B., Komanduri, K.V., MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood, 121, 2013, 4617.
167. [167] Cetkovic-Cvrlje, M., Uckun, F.M., Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br. J. Haematol., 126, 2004, 821.
168. [168] Docampo, M.D., Auletta, J.J., Jenq, R.R., Emerging Influence of the Intestinal Microbiota during Allogeneic Hematopoietic Cell Transplantation: Control the Gut and the Body Will Follow. Biol. Blood Marrow Transplant., 21, 2015, 1360.
169. [169] Wilhelm, K., Ganesan, J., Müller, T., Dürr, C., Grimm, M., Beilhack, A., Krempl, C.D., Sorichter, S., Gerlach, U.V., Jüttner, E., Zerweck, A., Gärtner, F., Pellegatti, P., Di Virgilio, F., Ferrari, D., Kambham, N., Fisch, P., Finke, J., Idzko, M., Zeiser, R., Graft-versus-host disease enhanced by extracellular adenosine triphosphate activating P2X7R. Nat. Med., 12, 2010, 1434.
170. [170] Qiao, J., Huang, Y., Xia, Y., Chu, P., Yao, H., Xu, L., Qi, K., Liu, Y., Xu, K., Zeng, L., Busulfan and cyclosphamide induce liver inflammation through NLRP3 activation in mice after hematopoietic stem cell transplantation. Sci. Rep., 5, 2015, 17828.
171. [171] Tsukamoto, H., Chernogorova, P., Ayata, K., Gerlach, U.V., Rughani, A., Ritchey, J.W., Ganesan, J., Follo, M., Zeiser, R., Thompson, L.F., Idzko, M., Deficiency of CD73/ecto-5’-nucleotidase in mice enhances acute graft-versus-host disease. Blood, 119, 2012, 4554.
172. [172] Wang, L., Fan, J., Chen, S., Zhang, Y., Curiel, T.J., Zhang, B., Graft-versus-host disease is enhanced by selective CD73 blockade in mice. PLoS ONE, 8, 2013, e58397.
173. [173] Jankovic, D., Ganesan, J., Bscheider, M., Stickel, N., Weber, F., Guarda, G., Follo, M., Pfeifer, D., Tardivel, A., Ludigs, K., Bouazzaoui, A., Kerl, K., Fischer, J., Haas, T., Schmitt-Gräff, A., Manoharan, A., Müller, L., Finke, J., Martin, S., Gorka, O., Peschel, C., Ruland, J., Idzko, M., Duyster, J., Holler, E., French, L.E., Poeck, H., Contassot, E., Zeiser, R., The Nlrp3-inflammasome regulates acute graft-versus-host disease. J. Exp. Med., 210, 2013, 1899.
174. [174] Yeh, A.C., Brunner, A.M., Spitzer, T.R., Chen, Y.B., Coughlin, E., McAfee, S., et al. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation. Biol. Blood Marrow Transplant., 20, 2014, 730.